Is It Too Late to Buy Regeneron (REGN) After Its 29% Rally?
Regeneron (REGN) stock has rallied 29.4% over the past year but is down 5.7% year-to-date. This article reviews the company's key metrics and pipeline developments to assess whether the stock still offers value.
Key Numbers
After delivering a one-year return of 29.4%, Regeneron Pharmaceuticals (REGN) has investors wondering if the easy gains are behind it. The stock currently trades around $732, but has declined 2.0% over the past week, 0.7% over the past month, and 5.7% year-to-date. Recent attention has centered on its core drug portfolio and pipeline developments, which continue to shape investor expectations for future cash flows.
Stock Performance
| Period | Return |
|---|---|
| 1 Year | +29.4% |
| YTD | -5.7% |
| 1 Month | -0.7% |
| 1 Week | -2.0% |
What's Driving the Stock?
Analysts are focused on Regeneron's drug portfolio, particularly Eylea for eye diseases, which accounts for a significant portion of revenue. The promising pipeline, including new treatments in oncology and immunology, also plays a role in stock valuation. Any positive or negative developments in clinical trials or regulatory approvals could impact the price.
Current Valuation
After the significant rally, Regeneron's stock may appear expensive relative to sector averages. However, the company's earnings strength and growth prospects could justify the premium. Investors need to weigh the potential risks of slowing Eylea growth against the opportunities from new drug launches.
What This Means for Investors
While the stock may have already captured some gains, Regeneron remains a company with strong fundamentals and a promising pipeline. The decision hinges on how investors assess the risk-reward balance going forward.
Frequently Asked Questions
Found this useful? Share it